Riskpilot← Back to searchSign inGet full accessDr Labaf AB
ABActiveOrg 5590938600John Lundvallsgatan 13Medical specialists activities · NACE 8622Est. 20160 employees
Revenue 2025
SEK 277K
+273% vs 2024
EBITDA margin
86.3%
+612% vs 2024
Equity ratio
83.0%
Financial strength
Net profit 2025
SEK 188K
+618% vs 2024
| Revenue | SEK 277K | +273% |
| EBITDA | SEK 239K | +612% |
| Net profit | SEK 188K | +618% |
| Total assets | SEK 461K | +2% |
| Equity | SEK 383K | +0% |
| Employees | 0 | — |
Legal name
Dr Labaf AB
Org number
5590938600
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
22 december 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall syssla med förvaltning, konsultverksamhet inom medicinsk utveckling och bedriva konsultverksamhet inom E-hälsa inom ramen för digitala beslutsstöd inom vården, digitalt anamnessystem, digital triagering och digitala läkarbesök samt därmed förenlig verksamhet.
Address
John Lundvallsgatan 13
Email
ashkan.labaf@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 10 | 59 | 165 | 74 | 277 |
| Staff expenses | — | −5 | −2 | −5 | −0 |
| EBITDA | −10 | 12 | 131 | 34 | 239 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −10 | 12 | 131 | 34 | 239 |
| Net financials | 282 | −0 | −0 | −0 | −1 |
| Profit before tax | 272 | 12 | 130 | 33 | 237 |
| Tax | −0 | — | −24 | −7 | −49 |
| Net profit | 272 | 12 | 106 | 26 | 188 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 701 | 456 | 435 | 450 | 461 |
| Equity | 695 | 435 | 358 | 384 | 383 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 6 | 21 | 77 | 66 | 78 |
| Total debt | 6 | 21 | 77 | 66 | 78 |
EBITDA margin
86.3%
This company
15.8%
Market median
+446% vs market
20212025
Equity ratio
83.0%
This company
38.2%
Market median
+117% vs market
20212025
Return on equity
49.2%
This company
18.4%
Market median
+167% vs market
20212025
Net profit margin
68.1%
This company
8.1%
Market median
+741% vs market
20212025
Asset turnover
0.60×
This company
1.12×
Market median
-46% vs market
20212025
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dr Labaf AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mojgan Sohrabi Nejad | Deputy Board Member | 0 companies |
| Ashkan Labaf | Board of Directors | 0 companies |